List of works - Donald R. VanDevanter

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients

scientific article

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients

scientific article published on 13 January 2015

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

scientific article (publication date: 22 June 2000)

Ability of Circular Extrachromosomal DNA Molecules to Carry Amplified MYCN Protooncogenes in Human Neuroblastomas In Vivo

scientific article published on 01 December 1990

Advancing clinical development pathways for new CFTR modulators in cystic fibrosis

scientific article

Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent?

scientific article published on December 2011

Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection

scientific article

Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site

scientific article published on 19 December 2014

Antipseudomonal treatment decisions during CF exacerbation management

scientific article published in 2022

Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis

scientific article

Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations ⬇️

scientific article published on October 6, 2010

Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes

scientific article published on 11 December 2014

Association of High-Dose Ibuprofen Use, Lung Function Decline, and Long-Term Survival in Children with Cystic Fibrosis

scientific article published on 9 January 2018

CFTR modulators and pregnancy: Our work has only just begun

scientific article published on 07 January 2016

Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995–2005

scholarly article by Donald R. VanDevanter et al published July 2013 in Journal of Cystic Fibrosis

Clinical applications of pulmonary delivery of antibiotics

scientific article

Culture-Based and Culture-Independent Bacteriologic Analysis of Cystic Fibrosis Respiratory Specimens

scientific article published on 23 December 2015

Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change

scientific article

Cystic fibrosis in young children: A review of disease manifestation, progression, and response to early treatment

scientific article

Decade-long bacterial community dynamics in cystic fibrosis airways

scientific article

Decline in lung function does not predict future decline in lung function in cystic fibrosis patients.

scientific article published on 18 June 2015

Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint.

scientific article

Design and powering of cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpoint

scientific article published on 19 June 2010

Determination of polymyxin E1 in rat plasma by high-performance liquid chromatography

scientific article published in June 2003

Efficacy measures for clinical trials: A review series

scientific article published on 15 June 2016

Electrophoretic isolation of extrachromosomal DNA from tumor cells

scientific article published on April 1995

Evidence of diminished FEV1 and FVC in 6-year-olds followed in the European Cystic Fibrosis Patient Registry, 2007-2009.

scientific article published on 28 April 2013

First bacterial infection as an alternative clinical end point for regulatory approval of agents targeting the primary cystic fibrosis defect

scientific article published in September 2005

How much do Pseudomonas biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis?

scientific article

IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis

scientific article published on 22 October 2015

Improvements in lung function and height among cohorts of 6-year-olds with cystic fibrosis from 1994 to 2012.

scientific article

Loss of DNA-membrane interactions and cessation of DNA synthesis in myeloperoxidase-treated Escherichia coli

scientific article

Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis

scientific article published on 20 November 2019

Microbial diversity in the cystic fibrosis airways: where is thy sting?

scientific article published in July 2012

Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.

scientific article

Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease.

scientific article published on January 2012

Potential for Therapeutic Benefit among Cystic Fibrosis Populations Excluded from Clinical Trials or Labeling of Marketed Therapies

scientific article published on 12 August 2016

Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis

scientific article published on 29 April 2016

Pulmonary outcome prediction (POP) tools for cystic fibrosis patients.

scientific article

Pure chromosome-specific PCR libraries from single sorted chromosomes.

scientific article published on June 1994

Relationship of Antibiotic Treatment to Recovery after Acute FEV1 Decline in Children with Cystic Fibrosis

scientific article published on 21 March 2017

Resolution of DNA fragments from 23 kilobases to 6 megabases by biphasic linear pulse ramping.

scientific article

Risk factors for rate of decline in FEV1 in adults with cystic fibrosis.

scientific article

Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection

scientific article

Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in children with cystic fibrosis.

scientific article published on 11 July 2014

The challenge of improving outcomes for patients with CF sinonasal disease

scientific article published on 02 June 2014

Tobramycin administered by the TOBI(®) Podhaler(®) for persons with cystic fibrosis: a review.

scientific article published on 20 September 2011

Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis

scientific article

Trends in the use of routine therapies in cystic fibrosis: 1995-2005.

scientific article published on 17 August 2010

Trisomy 8 in primary esthesioneuroblastoma

scientific article published on 01 November 1991

Unusual expression of mRNA typical of Philadelphia positive acute lymphoblastic leukemia detected in chronic myeloid leukemia

scientific article published on 01 July 1996

Y chromosome loss in chronic myeloid leukemia detected in both normal and malignant cells by interphase fluorescence in situ hybridization

scientific article published in November 1994

List of works by Donald R. VanDevanter

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

Ability of Circular Extrachromosomal DNA Molecules to Carry Amplified MYCN Protooncogenes in Human Neuroblastomas In Vivo

Advancing clinical development pathways for new CFTR modulators in cystic fibrosis

Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent?

Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection

Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site

Antipseudomonal treatment decisions during CF exacerbation management

Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis

Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations ⬇️

Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes

Association of High-Dose Ibuprofen Use, Lung Function Decline, and Long-Term Survival in Children with Cystic Fibrosis

CFTR modulators and pregnancy: Our work has only just begun

Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995–2005

Clinical applications of pulmonary delivery of antibiotics

Culture-Based and Culture-Independent Bacteriologic Analysis of Cystic Fibrosis Respiratory Specimens

Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change

Cystic fibrosis in young children: A review of disease manifestation, progression, and response to early treatment

Decade-long bacterial community dynamics in cystic fibrosis airways

Decline in lung function does not predict future decline in lung function in cystic fibrosis patients.

Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint.

Design and powering of cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpoint

Determination of polymyxin E1 in rat plasma by high-performance liquid chromatography

Efficacy measures for clinical trials: A review series

Electrophoretic isolation of extrachromosomal DNA from tumor cells

Evidence of diminished FEV1 and FVC in 6-year-olds followed in the European Cystic Fibrosis Patient Registry, 2007-2009.

First bacterial infection as an alternative clinical end point for regulatory approval of agents targeting the primary cystic fibrosis defect

How much do Pseudomonas biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis?

IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis

Improvements in lung function and height among cohorts of 6-year-olds with cystic fibrosis from 1994 to 2012.

Loss of DNA-membrane interactions and cessation of DNA synthesis in myeloperoxidase-treated Escherichia coli

Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis

Microbial diversity in the cystic fibrosis airways: where is thy sting?

Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.

Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease.

Potential for Therapeutic Benefit among Cystic Fibrosis Populations Excluded from Clinical Trials or Labeling of Marketed Therapies

Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis

Pulmonary outcome prediction (POP) tools for cystic fibrosis patients.

Pure chromosome-specific PCR libraries from single sorted chromosomes.

Relationship of Antibiotic Treatment to Recovery after Acute FEV1 Decline in Children with Cystic Fibrosis

Resolution of DNA fragments from 23 kilobases to 6 megabases by biphasic linear pulse ramping.

Risk factors for rate of decline in FEV1 in adults with cystic fibrosis.

Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection

Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in children with cystic fibrosis.

The challenge of improving outcomes for patients with CF sinonasal disease

Tobramycin administered by the TOBI(®) Podhaler(®) for persons with cystic fibrosis: a review.

Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis

Trends in the use of routine therapies in cystic fibrosis: 1995-2005.

Trisomy 8 in primary esthesioneuroblastoma

Unusual expression of mRNA typical of Philadelphia positive acute lymphoblastic leukemia detected in chronic myeloid leukemia

Y chromosome loss in chronic myeloid leukemia detected in both normal and malignant cells by interphase fluorescence in situ hybridization